Recently, Moderna (NASDAQ: MRNA)'s CEO highlighted a big risk for the company: Demand for its COVID-19 vaccine is going to crater. It's a big enough decline to get investors worried. Moderna is anticipating a big drop in demand this year as concerns around COVID-19 subside.
What makes a top growth stock? It's generated billions of dollars thanks to its coronavirus vaccine -- but the company has other major growth drivers on the way. Let's find out more about this ultimate growth stock to buy now.
When there are bargains on stocks with long-term appeal, astute investors make sure to get a few shares while the getting is good. In truth, Moderna (NASDAQ: MRNA) is a bit of a contrarian purchase at the moment as nobody expects it to one-up its 2022 top line of nearly $19 billion now that sales of its coronavirus vaccine are expected to fall to as low as $5 billion in 2023.